These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 27486981)

  • 21. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
    Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
    Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
    McCullough KB; Patnaik MM
    Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
    Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
    Tang G; Zhang L; Fu B; Hu J; Lu X; Hu S; Patel A; Goswami M; Khoury JD; Garcia-Manero G; Medeiros LJ; Wang SA
    Am J Hematol; 2014 Aug; 89(8):813-8. PubMed ID: 24782398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
    Jankowska AM; Makishima H; Tiu RV; Szpurka H; Huang Y; Traina F; Visconte V; Sugimoto Y; Prince C; O'Keefe C; Hsi ED; List A; Sekeres MA; Rao A; McDevitt MA; Maciejewski JP
    Blood; 2011 Oct; 118(14):3932-41. PubMed ID: 21828135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
    Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
    Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
    Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
    Patnaik MM; Wassie EA; Padron E; Onida F; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Komrokji R; Tefferi A; Solary E
    Blood Cancer J; 2015 Jan; 5(1):e270. PubMed ID: 25555161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
    Stem Cell Investig; 2016; 3():50. PubMed ID: 27777939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
    Ball M; List AF; Padron E
    Blood; 2016 Nov; 128(20):2381-2387. PubMed ID: 27707735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.